Company: SPRB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0000950170-25-055856
Chunk: 71

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 71
---
 is the beneficial owner of more than 5% of our outstanding capital stock. Bali Muralidhar, M.D., Ph.D. is a member of our board of directors and serves as Managing Partner of Abingworth LLP, an affiliate of Abingworth Bioventures VII LP. (4) HealthCap VIII, L.P. is the beneficial owner of more than 5% of our outstanding capital stock. Jonas Hansson, a former member of our board of directors, was formerly employed as a partner at HealthCap Advisor AB, an entity affiliated with HealthCap VIII, L.P. (5) Entities affiliated with Rock Springs Management LP collectively beneficially own more than 5% of our outstanding capital stock. (6) Armistice Capital Master Fund Ltd. is the beneficial owner of more than 5% of our outstanding capital stock. (7) 5AM Opportunities II, L.P. was the beneficial owner of more than 5% of our outstanding capital stock at the time of the financing.

<div align='center'>49</div>

Policies and Procedures for Transactions with Related Persons

We have adopted a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of the Board or our Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect interest, must be presented to the Board or our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, the Board or our Audit Committee is to consider the material facts of the transaction, including whether the transaction is on terms comparable to the terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

<div align='center'>50</div>

### HOUSEHOLDING OF PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers)